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Abstract
Background: Thrombosis is the fatal and disabling consequence of cardiovascular diseases, the leading cause of
mortality and morbidity in Western countries. Two inbred mouse strains, C57BL/6J and A/J, have marked
differences in susceptibility to obesity, atherosclerosis, and vessel remodeling. However, it is unclear how these
diverse genetic backgrounds influence pathways known to regulate thrombosis and hemostasis. The objective of
this study was to evaluate thrombosis and hemostasis in these two inbred strains and determine the phenotypic
response of A/J chromosomes in the C57BL/6J background.
Methods: A/J and C57Bl/6J mice were evaluated for differences in thrombosis and hemostasis. A thrombus was
induced in the carotid artery by application of the exposed carotid to ferric chloride and blood flow measured
until the vessel occluded. Bleeding and rebleeding times, as surrogate markers for thrombosis and hemostasis,
were determined after clipping the tail and placing in warm saline. Twenty-one chromosome substitution strains,
A/J chromosomes in a C57BL/6J background, were screened for response to the tail bleeding assay.
Results: Thrombus occlusion time was markedly decreased in the A/J mice compared to C57BL/6J mice. Tail
bleeding time was similar in the two strains, but rebleeding time was markedly increased in the A/J mice compared
to C57BL/6J mice. Coagulation times and tail morphology were similar, but tail collagen content was higher in A/
J than C57BL/6J mice. Three chromosome substitution strains, B6-Chr5A/J, B6-Chr11A/J, and B6-Chr17A/J, were
identified with increased rebleeding time, a phenotype similar to A/J mice. Mice heterosomic for chromosomes 5
or 17 had rebleeding times similar to C57BL/6J mice, but when these two chromosome substitution strains, B6-
Chr5A/J and B6-Chr17A/J, were crossed, the A/J phenotype was restored in these doubly heterosomic progeny.
Conclusion: These results indicate that susceptibility to arterial thrombosis and haemostasis is remarkably
different in C57BL/and A/J mice. Three A/J chromosome substitution strains were identified that expressed a
phenotype similar to A/J for rebleeding, the C57Bl/6J background could modify the A/J phenotype, and the
combination of two A/J QTL could restore the phenotype. The diverse genetic backgrounds and differences in
response to vascular injury induced thrombosis and the tail bleeding assay, suggest the potential for identifying
novel genetic determinants of thrombotic risk.
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Background
Family history [1] is the strongest risk factor for cardiovas-
cular diseases (CVD). While a number of genetic muta-
tions have been identified, these account for only a small
percentage of the CVD in human populations. Thrombus
formation on fissured atherosclerotic plaques is the pre-
cipitating event in the transition from a stable or subclin-
ical atherosclerotic disease and leads to acute myocardial
infarction, ischemic stroke or peripheral arterial occlu-
sion. Arterial and venous thrombosis are complex
responses and are influenced by multiple genetic and
environmental factors [2-5]. Polymorphisms and muta-
tions in coagulation factors, fibrinolytic factors, platelet
surface receptors, methylenetetrahydrofalate reductase,
endothelial nitric oxide synthase, and antioxidant
enzymes have been implicated as genetic determinants of
susceptibility to thrombosis [6,7]. Great strides have been
made in the diagnosis and treatment of thrombosis in the
last decade. However, strategies to prevent thrombosis
have lagged far behind due, in part, to the contribution of
multiple, and as yet undefined, genetic factors that lead to
thrombotic risk. Moreover, it remains unclear how genetic
background influences the function of molecules and
pathways known to regulate thrombus formation and
lysis and, thereby, contributes to the risk of thrombotic
disease.
Many of the available inbred mouse strains, such as
C57BL/6J (B6) and A/J, have been classified as resistant or
susceptible to particular complex diseases (Table 1). These
two strains have diverse responses to diet-induced obesity
[8] (B6 susceptible; A/J resistant), diet-induced atheroscle-
rosis (B6 susceptible; A/J resistant) [9], arterial ligation-
induced neointimal hyperplasia (B6 resistant; A/J resist-
ant), and ligation induced vessel remodeling (B6 resist-
ant; A/J susceptible) [10]. These conditions are
predisposing to thrombosis per se, but these mice have
not been systematically evaluated for thrombosis. Clot
formation and lysis, which ultimately determine throm-
bosis, requires platelet aggregation, coagulation, and fibri-
nolytic functions. Interactions among these pathways
may occur and additional factors may modulate these
processes. Identification of novel modulators and factors
of these pathways can be identified by associating the phe-
notype with a location(s) on a specific chromosome, a
quantitative trait locus (QTL).
A panel of chromosome substitution strains (CSS) was
generated [11] by a "marker-assisted" breeding program
where the progeny of a B6 × A/J cross were successively
backcrossed to the B6 mice. Genetic markers were used to
identify homozygosity in the background (B6) and the
individual A/J chromosome. These strains have one chro-
mosome from A/J mice in a B6 background. This allows
the identification of a trait in one or more CSS and implies
that at least one QTL resides on this chromosome. Use of
this panel requires fewer mice to determine the QTL than
does a genome-wide scan. Another advantage is the ability
for detection of QTL in the presence of other QTL. In addi-
tion, initial screens with the CSS simplify the fine-map-
ping of QTL. Several studies of this CSS panel, B6 Chr1-
19, X, YA/J, have been reported for behavior [12], weight
gain [13], sterols [13], and plasma amino acids levels
[13,14], and have identified many more QTL than studies
of the same traits using a genome-wide scan.
The purpose of this study was to evaluate the two inbred
strains of mice for prothrombotic risk, utilizing a ferric
chloride vascular injury model, tail bleeding assay, and
measures of coagulation and fibrinolysis. The results of
this study indicate that the two inbred strains, B6 and A/J
mice, have diverse prothrombotic phenotypes, unrelated
to coagulation or platelet aggregation. In addition, in the
CSS, expression of the A/J phenotypes, rebleeding time
and arterial occlusion, was modified in the B6 back-
ground, and suggested that interactions occurred among
the A/J QTL. Thus, it should be possible to identify inde-
pendent genetic determinants of susceptibility to patho-
logical haemostasis and thrombosis.
Methods
Mice
The inbred strains, B6 (#000664), Lepob (#000632), A/J
(#000646) and gene-targeted plasminogen (Plg) activator
inhibitor deficient mice (PAI-1-/-) (#002507) [15] mice
in a B6 background were obtained from Jackson Labora-
tory (Bar Harbor, Maine) at 6 wks-of-age. The Plg-/- mice
were generated as previously described [16] and main-
Table 1: Identification of mice susceptible or resistant to obesity, atherosclerosis, and vascular injury
Mouse Strain/Genotype Diet-induced Obesity Diet-induced Atherosclerosis Neointimal Hyperplasia Vessel Remodeling
C57BL/6J (B6) S [8] S [9] R [10] R [10]
A/J R [8] R [9] R [10] S [10]
Lepob S [41] S [42] R [43] R [43]
Plg-/- R [44] S (apoE-/-) [45]
R (transplant) [46]
R [47,48] R [48]
PAI-1-/- S [18] R [49,50] R [50] R [50]
R: resistant; S: susceptible. Reference provided by number in parenthesis. Lepob, Plg-/-, and PAI-F1-/- mice were in a B6 background.BMC Blood Disorders 2006, 6:6 http://www.biomedcentral.com/1471-2326/6/6
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tained in the B6 background, generated by crossing mice
from the original mixed (B6:129) background for eight
generations with B6 mice. The Plg-/- mice do not repro-
duce well and Plg heterozygous pairs were used for breed-
ing. Genotypes (Plg+/+, Plg+/-, Plg-/-) of the offspring
were determined by a PCR assay at 3–4 weeks-of-age from
an ear punch [17]. Breeding pairs of the CSS mice were
transferred from Dr. Nadeau's laboratory. All mice were
housed and bred in the Biological Resource Unit at the
Cleveland Clinic Foundation (CCF). Mice were housed in
sterilized isolator cages, maintained on a 14 hr light/10 hr
dark cycle, and were provided sterilized food and water ad
libitum. Mice were fed a standard autoclavable laboratory
diet consisting of: 23% protein, 4.5% fat, 6% fiber,
(Purina, St. Louis, MO), and tested between 7 and 9 wks-
of-age. All animal experiments were performed in accord-
ance with a protocol approved by the Institutional Animal
Care and Research Advisory Committee at CCF.
Vascular injury
To induce thrombosis formation in the carotid artery, a
ferric chloride (FeCl3) model of vessel injury [18,19] was
employed. Mice were anesthetized with ketamine/xyla-
zine (80 mg/kg, 5 mg/kg), a midline cervical incision was
made and the left common carotid artery isolated by
blunt dissection. The flow probe (Transonic Systems,
model 0.5PSB) was placed under the artery and when a
stable baseline was reached, a 0.5 × 2 mm strip of filter
paper saturated with 10% FeCl3 solution was applied to
the surface of the carotid artery for 3 min. Occlusion time
was determined from the addition of the FeCl3 solution to
the occlusion of the artery (minimum blood flow). The
flow probe was in place from the establishment of the
baseline until several min after the stable occlusion had
been reached or stopped at 30 min if it had not occluded.
Blood flow was recorded every 10 sec (Transonic Systems,
model TS420). There was no difference in body weight
among the mice that were tested in the vascular injury
model.
Bleeding and rebleeding assay
For the tail bleeding assay, mice were anesthetized with
ketamine/xylazine (80 mg/kg, 5 mg/kg), the tail pre-
warmed for 5 min in 10 mL of saline at 37°C in a water
bath. The tail was lifted from the saline and a 5 mm tail
segment amputated and immediately returned to the
saline. Bleeding time was measured as the time between
the start of bleeding to cessation of bleeding. With the tail
remaining in the same saline solution, the rebleeding
time was measured from the time between bleeding cessa-
tion and the start of the second bleeding.
Coagulation, Plg, α2-antiplasmin, fibrinogen, fibrinolytic 
and PAI-1 assays
Mice were anesthetized with Isoflurane (Abbott), bled
from the orbital sinus into uncoated capillary tubes, and
a drop of blood immediately placed on a reagent strip
(Synbiotics) for prothrombin time (PT) or activated par-
tial thromboplastin time (aPTT) determinations and
inserted into the precalibrated Coagulation Analyzer
(SCA2000, Synbiotics). PAI-1 activity was determined
according to the method of Chandler et al [20]. PAI-1 anti-
gen concentration was determined by ELISA [21] using
sheep-anti mouse PAI-1 (American Diagnostica) as the
capture antibody and mouse PAI-1 (American Diagnos-
tica) as the standard (0–3.5 ng/mL). Plg was determined
with a chromogenic assay [22] and the fibrinolytic activity
determined by fibrin degradation [23]. For the negative
controls in these assays, plasma from PAI-1 or Plg defi-
cient mice was used. Functionally active mouse α2-
antiplasmin was determined with a plasmin capture assay
and detection with a mouse antibody (Molecular Innova-
tions, Southfield, MI), and fibrinogen with an ELISA assay
with antibodies that recognize mouse fibrinogen
(Hyphen BioMed, France).
Histochemical and immunohistochemistry analysis
The frozen tails or injured carotids in OCT were sectioned
at 5 μm thickness and stained with Masson's Trichrome
(HT 15, Sigma Diagnostics). For quantitative analysis of
collagen area in the tail sections, four sections from 2–3
sites were measured using computer assisted image analy-
sis (Image-Pro Plus, Cybernetics). For the area determina-
tion of the injured carotid lumen, 3–4 sections from
different sites approximately 100 μm apart were analyzed
and averaged for each mouse.
Statistics
Data are presented as mean ± SEM. The statistical analysis
for comparisons between A/J and B6 mice and between
wild-type (WT) and Plg-/- littermates was compared with
a two-tailed t-test. Differences among B6, Lepob, PAI-1-/-
mice were determined by a one-way ANOVA and a New-
man-Keuls post-test. A value of P < 0.05 was considered
significant. The statistical analysis for comparisons
between B6 mice and CSS were determined with two-tail
t-tests and the level of the significant P-values (see figure
legends) determined with a Bonferroni correction to
account for multihypothesis testing [13].
Results
Marked differences in arterial thrombus formation in B6 
and A/J mice
The FeCl3 cartoid artery injury model [24], a well-charac-
terized arterial thrombosis model, was used to induce an
occlusive thrombus in the B6 and A/J mouse strains under
investigation. A marked difference in arterial thrombusBMC Blood Disorders 2006, 6:6 http://www.biomedcentral.com/1471-2326/6/6
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occlusion time was found between the B6 and the A/J
mice (Figure 1A). The occlusion time in the A/J mice was
2-fold less than for the B6 mice. A 5% dose of FeCl3 was
tested in the A/J and B6 mice and the occlusion time was
lower in the A/J than the B6 mice, the same results as with
the 10% dose. The occlusion time (min for both B6 (15 ±
3, n = 3) and A/J (8 ± 1, n = 3) at 5% were longer than at
10% for B6 (10 ± 1, n = 17 and A/J (5 ± 2, n = 14). The
curves of blood flow after FeCl3 application indicated a
pattern with a gradual decrease before occlusion for the
B6 mice (Figure 1B), but for the A/J mice the blood flow
decreased abruptly to zero (Figure 1C), demonstrating a
marked difference from the B6 strain. The mean occlusion
times were significantly different between the two strains
(Figure 1A). The size of the carotids in the two strains was
noticeably different. The area (mm2) of the lumen (0.066
± 0.007, n = 6) was significantly less in the A/J mice than
for B6 mice (0.128 ± 0.007, n = 6). However, the ratio of
the thrombus to lumen was similar for A/J (0.63 ± 0.03)
compared to B6 mice (0.67 ± 0.09). Calculated sheer
stress rates [25] were 14% less in the A/J mice when com-
pared to B6 mice.
Marked differences in rebleeding time in B6 and A/J mice
The bleeding time, an indicator of hemostatic activity, was
determined after prewarming the tail, clipping a 5 mm
segment, placing the tail in warm saline and measuring
the time for the bleeding to stop. We found this procedure
was consistent and reproducible in different mouse
strains and was not gender dependent. Bleeding time was
not different in A/J mice compared to B6 mice (Figure
2A). In order to determine if specific pathways were
altered in the B6 and A/J strains, mice with known altera-
tions in hemostasis, Lepob mice, or thrombosis, Plg-/- and
PAI-/- mice, were also tested. The Lepob  mice have
impaired platelet aggregation [26] and were evaluated as
a reference for platelet function. In the Lepob mice (Figure
2A) there was nearly a 10-fold increase in bleeding time
compared to B6 mice. Bleeding time was also significantly
(P = 0.0001) increased by 66% in the Plg-/- mice com-
pared to WT mice littermates. Bleeding time was not dif-
ferent in PAI-1-/- mice compared to B6 mice. In contrast
to the Lepob  mice with a platelet defect and 10-fold
increase in bleeding time, there was no difference in the
bleeding time between B6 and A/J mice and suggested
platelet aggregation is not altered in these two strains.
Rebleeding time, an indicator of thrombus stability, was
measured as the time between the cessation of bleeding
and the start of the second bleeding (Figure 2B). Rebleed-
ing times were significantly higher in A/J (2.6-fold, P <
0.001) mice than the B6 mice. In contrast, the rebleeding
time was nearly 8.5-fold less in the Lepob mice than the B6
mice. To determine how alterations in the fibrinolytic sys-
tem may affect rebleeding time, Plg-/- and PAI-1-/- mice
were also tested (Figure 2B). Rebleeding time was not dif-
ferent in Plg-/- mice compared to WT littermates, but PAI-
1-/- mice had a significantly (P < 0.05) reduced rebleeding
time, which was 1.8-fold lower than for the B6 mice.
Although a Plg deficiency did not result in a prolonged
rebleeding time as anticipated, a PAI-1 deficiency resulted
in a shortened time. The markedly increased rebleeding
time in the A/J may suggest differences in the regulation of
the Plg network.
Arterial occlusion time in B6 and A/J mice Figure 1
Arterial occlusion time in B6 and A/J mice. Panels A and B are representative occlusion curves from each genotype. 
Red arrows indicate duration of ferric chloride application to the carotid. Panel A: B6 mice, Panel B: A/J mice. Panel C: 
Arterial occlusion time, mean ± SEM of 14–17 mice per genotype. Symbol indicates a significant difference (**P < 0.01) between 
B6 mice determined with a t-test.BMC Blood Disorders 2006, 6:6 http://www.biomedcentral.com/1471-2326/6/6
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No difference in blood coagulation between B6 and A/J 
mice
To determine if differences in coagulation were contribut-
ing factors to the bleeding and rebleeding results, pro-
thrombin time (PT) and activated partial thromboplastin
time (aPTT) were measured. PT is a measurement of the
extrinsic coagulation pathway (activation of Factor VII by
tissue factor) while aPTT is a measurement of the intrinsic
pathway (activation of Factors XII, XI, IX and VIII). The
products of both pathways activate Factor X, which initi-
ates the common pathway leading to thrombin genera-
tion and fibrin clot formation. PT and aPTT were
measured in the B6 and A/J mice and values were not dif-
ferent between the two mouse strains (Table 2). These
results suggest that the coagulation pathway is not differ-
ent in the two inbred strains.
Plg and PAI-1 higher in A/J than B6 mice
Plg concentration was 34% higher in the A/J mice than in
B6 mice. In addition, fibrinolytic activity, PAI-1 activity,
and α2-anitplasmin were also increased in the A/J mice
when compared to the B6 mice (Table 2). The functional
consequences of these differences are not clear, since
fibrinogen is also higher in the A/J mice. To determine
whether there were protein structure changes of Plg from
the A/J mice, plasma from the B6 and the A/J mice were
subjected to electrophoresis under reduced, non-reduced,
and non-denaturing conditions. No difference in migra-
tion for immunostained Plg under these conditions was
observed (data not shown). The density of the Western
blot from SDS-PAGE under reducing conditions of
plasma of varying volumes from B6 and A/J mice was
compared and the density of the bands was 56% higher in
Bleeding and rebleeding time in B6, A/J, Lepob, Plg-/- and PAI-1-/- mice Figure 2
Bleeding and rebleeding time in B6, A/J, Lepob, Plg-/- and PAI-1-/- mice. Panel A, B: Bleeding time (seconds) and 
Panel C, D: Rebleeding time (seconds). To determine statistical differences, values from B6 and A/J and from WT and Plg-/- 
littermates were compared with a t-test, and values from B6, PAI-1-/- and Lepob were compared by a one-way ANOVA and a 
Newman-Keuls post-test. Symbols indicate a significant difference (*P < 0.05, **P < 0.01, ***P < 0.001) between B6 or WT 
mice. Values are the mean ± SEM of 10–34 mice per genotype.BMC Blood Disorders 2006, 6:6 http://www.biomedcentral.com/1471-2326/6/6
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the A/J than the B6 mice (six individual mice were tested
on at least two occasions) from the same amount of
plasma (Fig. 1B). Thus, the concentration of Plg in plasma
from the A/J mice was higher than plasma from the B6
mice as determined by two methods and no difference in
migration after electrophoresis was observed, suggesting
no marked changes in the structure of Plg in the two
mouse strains.
Tail morphology in B6 and A/J
The tails of the mice were examined for differences that
might account for the variations in the bleeding and
rebleeding values. Sections of the tail from the B6 and A/J
mice were stained with Hematoxylin/Eosin or Masson's
Trichrome and representative sections are shown in Figure
3. No obvious qualitative differences were observed in
hair follicles, sebaceous glands, or center bone/cartilage in
Hematoxylin/Eosin (Figure 3A) stained sections. Sections
of the tails were stained with Masson's Trichrome (Figure
3B) that detects collagen, the major platelet adhesive sub-
stratum for initiation of thrombus formation. Collagen
content (% tail area) was quantified (Figure 3C) from 3–
4 sections from 2–3 areas/mouse. The amount of collagen
was greater in the A/J than the B6 mice (P < 0.05). Colla-
gen in vessels in adipose tissue in the A/J mice is also
increased compared to the B6 mice (data not shown).
Tail bleeding assay identifies three chromosomes with QTL 
for rebleeding in CSS
Using the tail bleeding/rebleeding assay as a surrogate
marker for hemostasis and thrombosis, the CSS were
screened. The bleeding times (Figure 4A) for the B6 and
the A/J mice were not different, but 6six of the strains, B6-
Chr5, 6, 8, 14, 15, and YA/J, had lower (P < 0.002) bleed-
ing times (49–79 seconds) compared to the value for the
B6 mice (121 sec). The rebleeding time (Figure 4B), deter-
mined as the time between bleeding cessation and initia-
tion of the second bleeding, was markedly increased in
the A/J mice compared to the B6 mice and two strains, B6-
Chr11A/J (CSS-11) and B6-Chr17A/J (CSS-17), had signifi-
cantly (P < 0.002) longer rebleeding times compared to
the B6 mice that were similar to values from the A/J mice.
Another strain, B6-Chr5A/J (CSS-5), approached signifi-
cance at P < 0.008. The rebleeding time was stopped at
600 sec, and the percentage of mice with this value deter-
mined for the three strains: CSS-5–60%, CSS-11–60% and
CSS-A17–46%. The percentage of B6 mice with a rebleed-
ing time of 600 sec was 7% and for the A/J mice the per-
centage was 85%.
Rebleeding time in the parent strains and CSS were com-
pared to values from the progeny of mice that were
crossed with B6 mice to produce heterosomic mice for the
CSS-5, (B6xCSS-5)F1 and CSS-17 (B6xCSS-17)F1 strains
(Figure 5). The rebleeding values for CSS-5F1 and CSS-
17F1 mice were similar to the B6 rather than the A/J mice,
suggesting the A/J trait is recessive. Bleeding and rebleed-
ing in the progeny of the cross, B6-Chr5A/J × B6-Chr17A/J
(CSS-5 × CSS-17) resulted in the recovery of the A/J phe-
notype in the progeny of these double heterosomic
strains. Thus, despite the heterosomic chromosomes of 5
and 17 in the progeny of the CSS-5 × CSS-17, the pheno-
type was now similar to A/J. This suggested that traits on
the A/J chromosomes were interacting to produce the phe-
notype.
Interactions of CSS for PAI-1 antigen and activity
Components of the Plg system reside on chromosomes
CSS-5 (PAI-1), CSS-11 (α2-antiplasmin), and CSS-17
(Plg). As reported in Table 2, the A/J mice had increased
Plg antigen, fibrinolytic activity, α2-antiplasmin, PAI-1
activity and fibrinogen when compared to B6 mice. In
CSS-17 mice, the Plg antigen was also significantly (P =
0.015) increased (152 ± 6, n = 12) when compared to the
B6 mice, but for CSS-5 and CSS-5 × 17, the Plg antigen
was similar to values for the B6 mice. Fibrinolytic activity
was not different in the CSS-5 or CSS-17 strains compared
to the B6 mice. α2-antiplasmin was significantly (P = <
0.01) reduced in CSS-5 mice (142 ± 4 μg/mL, n = 5), sig-
nificantly (P < 0.05) higher in the CSS-11 (201 ± 6, n = 8),
but not different in CSS-17 or CSS-5 × 17 mice compared
to the B6 mice.
Table 2: Coagulation and Plasminogen System Parameters in B6 and A/J inbred mouse strains
B6 A/J
Prothrombin Time (sec) 17 ± 1 18 ± 1
aPTT Time (sec) 66 ± 3 61 ± 7
Plasminogen (μg/mL) 131 ± 5 176 ± 9**
Fibrinolytic Activity (nM) 2.6 ± 0.1 3.0 ± 0.1*
PAI-1 Antigen (ng/mL) 7.4 ± 0.7 7.5 ± 0.7
PAI-1 Activity (U/mL) 185 ± 10 229 ± 8**
α2-antiplasmin (μg/mL) 170 ± 6 195 ± 5**
Fibrinogen (ng/mL) 1.6 ± 0.04 1.7 ± 0.05*
Values are the mean ± SEM. *P < 0.05, **P < 0.01. n = 5–8.BMC Blood Disorders 2006, 6:6 http://www.biomedcentral.com/1471-2326/6/6
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PAI-1 antigen and activity were determined in the CSS
with increased rebleeding times, CSS-5, CSS-11, and CSS-
17 (Figure 6), the heterosomic, CSS-5F1, CSS-17F1, and
double hetersomic, CSS-5 × 17. CSS-5, CSS-17, CSS-5F1,
and CSS-17F1 generally had reduced PAI-1 antigen when
compared to B6 mice. The reduced PAI-1 antigen was a
dominant trait due to the fact that the values were similar
in the homosomic and heterosomic CSS-5 and CSS-17.
The CSS-5 × CSS-17 double heterosomic strains had val-
ues similar to the B6 and A/J parent strains. PAI-1 activity
was significantly reduced in the CSS-5 and CSS-17F1
mice, but again in the CSS-5 × CSS-17 strain the value for
PAI-1 activity was restored to the value of the B6 and A/J
parent strains. The PAI-1 antigen (5.4 ng/mL ± 0.5, n = 7)
and activity (170 U/mL ± 20, n = 6) in the CSS-11 mice
was not different than for B6 mice.
Interactions of CSS for arterial thrombus formation
The tail bleeding assay was rapid and facilitated the
screening of the 21 CSS strains, and subsequently the
identified strains were tested for arterial occlusion after
the FeCl3 injury (Figure 7). The CSS-5 and CSS-17 had
occlusion times similar to the B6 mice, but the doubly
heterosomic CSS-5 × CSS-17 progeny had occlusion times
higher than either the B6 mice or the heterosomic CSS-
5F1 and CSS-17F1 or the A/J strains. In double hetero-
somic CSS-5 × CSS-17 mice, only one or three mice tested
had occluded by 30 min; the other two mice did not
occlude by 30 min. While only a small number of CSS
mice have been tested for the arterial occlusion, the results
suggest that interaction of the genes on chromosome 5
and 17 also determines arterial occlusion time.
Discussion
In this study, thrombotic risk was systematically assessed
in two inbred strains of mice that have marked differences
in susceptibility to diet-induced obesity, diet-induced
atherosclerosis, and ligation-induced neointimal hyper-
plasia and vessel remodeling. Arterial occlusion time, tail
bleeding and rebleeding time were evaluated as potential
predictors of thrombotic response. Assessments of the two
inbred strains were compared to values from gene targeted
mice of the Plg network with altered fibrinolytic
responses, as well as in leptin deficient mice with a
reduced platelet function. Marked differences were found
in the thrombotic response among the two inbred strains,
B6 and A/J, and the observed differences were not corre-
lated with change in coagulation or platelet function.
Screening the CSS identified three chromosomes that har-
bored genes which contributed to the A/J phenotype of
increased rebleeding time. Mice homosomic for these
chromosomes or doubly heterosomic for two of the chro-
mosomes, 5 and 17, were required to express the A/J phe-
notype, elevated rebleeding time. PAI-1 antigen and
activity were decreased in both CSS-5 and CSS-17 and the
heterosomic mice, CSS-5F1 and CSS-17F1, but not in the
CSS-11 strain. Values were restored in the doubly hetero-
somic for two of chromosomes, 5 and 17. Arterial occlu-
sion time was similar to B6 in the CSS-5 and CSS-17
homozygous strains, but increased in doubly heterosomic
for two of chromosomes, 5 and 17.
The FeCl3-induced model of vascular injury and thrombo-
sis in mice is now widely used to evaluate genetic and
Tail morphology and collagen Figure 3
Tail morphology and collagen. Tails were excised, 
embedded in OCT, sectioned, and stained with Hematoxylin/
Eosin or Masson's Trichrome. Panel A: Representative sec-
tions stained with hematoxylin and eosin from B6 and A/J 
mice. Panel B: Representative sections stained with Mas-
son's Trichrome from B6 and A/J mice. The blue color identi-
fies the collagen. Panel C: The percentage of the collagen 
area (excluding center bone/cartilage) of the total tail area of 
each section was determined in 3–4 sections at 2–3 sites for 
each tail and averaged for each mouse. Values are the mean 
± SEM of 4–8 mice per genotype. Symbol indicates a signifi-
cant difference (*P < 0.05) between B6 mice determined by t-
test.BMC Blood Disorders 2006, 6:6 http://www.biomedcentral.com/1471-2326/6/6
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pharmacological interventions [24]. The two inbred
strains had marked differences in the time for occlusion of
the carotid artery after FeCl3 injury. After FeCl3 treatment,
thrombus formation and occlusion was remarkably short-
ened in the A/J mice compared to the B6 mice. These
results have not previously been reported. A recent study
[25] of sheer stress in rats, found that the magnitude of
changes in sheer stress with increased blood flow varied
with the different strains. Further investigation, beyond
the scope of this study would be necessary to determine
the contribution in the differences in size and sheer stress
of the carotids to arterial occlusion rates in the B6 and A/
J mice. In preliminary studies, we have noted differences
in the composition of the thrombus in B6 and A/J mice.
The pattern of blood flow cessation for the two inbred
strains was different than for the Lepob mice [26] with
impaired platelet function, and coagulation time was sim-
ilar in the two strains. In the mice with deficiencies of the
Plg network [27], thrombus formation time was reduced
in the Plg-/- mice, but increased in the PAI-/- mice, sug-
gesting that alterations in plasmin activity that affect the
rate of clot lysis, can modulate the events leading to occlu-
sive thrombus formation.
The tail-bleeding assay has been used extensively in mice
to assess the impact of deficiencies and over expression of
platelet and coagulation proteins in mice. Sweeny et al
[28] screened 25 strains of mice and found only the RIIS/
J mice to have increased bleeding time due to reduced von
Willebrand antigen. Broze et al [29] evaluated mice with
gene deletions of the coagulation pathway and found that
while bleeding time was not increased, rebleeding per-
sisted despite electrocautery of the tail in FVIII and FIX
deficient mice. This observation raised the possibility that
rebleeding time may be a sensitive reporter of genetic
influences on thrombus formation and stability. Mice that
are deficient in factors required for normal platelet func-
tion, platelet glycoprotein Ib [30], and protease-activated
receptor-4, [31] have increased tail bleeding time. The lep-
tin deficiency with reduced platelet aggregation clearly
shows a marked increase in bleeding time and the
increased bleeding time in Plg-/- and uPA-/- mice suggests
Bleeding and rebleeding time in the CSS Figure 4
Bleeding and rebleeding time in the CSS. Panel A: Bleeding Time (seconds). Panel B: Rebleeding Time (seconds). Bars 
are the mean ± SEM of 7–28 mice. Statistical differences between B6 mice and CSS were determined with a t-test, and a Bon-
ferroni correction was made to determine significance value (P < 0.002). Symbols indicate a significant difference between B6 
values. *P < 0.002.
Bleeding and rebleeding time in the CSS backcrosses Figure 5
Bleeding and rebleeding time in the CSS backcrosses. Panel A: Bleeding Time (seconds) and Panel B: Rebleeding 
Time (seconds) were tested in heterosomic mice, (B6xCSS-5)F1 (5F1) and (B6xCSS-17)F1 (17F1) and doubly heterosomic 
mice for chromosomes 5 and 17 (5 × 17). Bars are the mean ± SEM of 5–28 mice. Statistical differences between B6 mice and 
the CSS were determined with a t-test, and a Bonferroni correction was made to determine significance value (P < 0.01). Sym-
bols indicate a significant difference between B6 values. *P < 0.01.BMC Blood Disorders 2006, 6:6 http://www.biomedcentral.com/1471-2326/6/6
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that Plg and uPA may exert an influence on platelet
response to promote normal thrombus formation. Over-
all, the marked increase in rebleeding times observed in
certain mouse strains suggests genetic factors other than
coagulation may play a role in the stability of a thrombus.
In the tail bleeding assay, A/J mice did not have changes
in bleeding time, but rebleeding time was higher com-
pared to B6 mice. In our study, Plg-/- mice had increased
bleeding time, PAI-1-/- had decreased rebleeding time,
and uPA-/- mice had an increased bleeding time similar to
the Plg-/- mice (J. Hoover-Plow, A. Shchurin, and E. Hart,
unpublished results). Increased bleeding or rebleeding
times have not been reported in any of the Plg network
targeted mice. Matsuno et al [32] reported no difference in
bleeding time for tPA-/-, uPA-/-, PAI-1-/- mice compared
to WT mice, and the assay was similar, but the tail clip seg-
ment was considerably shorter and bleeding times
reduced compared to the times reported in our study.
Bleeding time has not been previously reported for Plg-/-
mice. We have found similar values for Plg-/- mice in a
50%B6:50%129 background (J. Hoover-Plow, A.
Shchurin, and E. Hart, unpublished results). The results of
this study suggest that not only is bleeding time geneti-
cally determined by background, but also that tail
rebleeding time is genetically determined.
While blood pressure could conceivably be higher in mice
with elevated tail bleeding time, several studies suggest
that this is not the case. Studies of A/J [33-36] mice have
reported either decreased blood pressure or no difference
compared to the B6 mice. Blood pressure was measured in
the Plg-/- mice (D. Hellard, J. Hoover-Plow, and E. Plow,
unpublished results), and these mice have reduced blood
pressure when compared to WT littermates, and uPA-/-
[37] and Lepob [38,39] mice also have reduced blood pres-
sure, but there is no correspondence between blood pres-
sure and tail bleeding or rebleeding times. Morphometric
analysis of the tail indicated a difference in the collagen
content of the tail in the A/J mice. Differences in the struc-
ture and/or metabolism of collagen or extracellular matrix
proteins may contribute to the increased rebleeding and
reduced occlusion time in the A/J mice and warrant fur-
ther investigation.
The genes for Plg, PAI-1, and α2-antiplasmin reside on the
three chromosomes identified for QTL for rebleeding time
and may or may not be coincidental to the observed phe-
notypes found in the A/J mice and CSS. It is not likely that
merely the concentration of these components explains
the increased rebleeding time and reduced arterial occlu-
sion time in the A/J mice. When compared to the B6 mice,
the A/J mice and the three strains with elevated rebleeding
time had variable Plg, PAI-1, and α2-antiplasmin. Two
PAI-1 in the CSS backcrosses Figure 6
PAI-1 in the CSS backcrosses. Panel A: Plasma PAI-1 antigen (ng/mL) and Panel B: Plasma PAI-1 activity (U/mL) were 
tested in heterosomic mice, (B6xCSS-5)F1 (5F1) and (B6xCSS-17)F1 (17F1) and doubly heterosomic mice for chromosomes 5 
and 17 (5 × 17). Bars are the mean ± SEM of 5–18 mice. Statistical differences between B6 mice and CSS were determined with 
a t-test, and a Bonferroni correction was made to determine significance value (P < 0.01). Symbols indicate a significant differ-
ence between B6 values. *P < 0.01.
Arterial occlusion time in the CSS backcrosses Figure 7
Arterial occlusion time in the CSS backcrosses. 
Occlusion time was determined in heterosomic mice, 
(B6xCSS-5)F1 (5F1) and (B6xCSS-17)F1 (17F1), and doubly 
heterosomic mice for chromosomes 5 and 17 (5 × 17). Bars 
are the mean ± SEM of 5–18 mice. Statistical differences 
between B6 mice and CSS were determined with a t-test, 
and a Bonferroni correction was made to determine signifi-
cance value (P < 0.02). Symbols indicate a significant differ-
ence between B6 values. *P < 0.0001.BMC Blood Disorders 2006, 6:6 http://www.biomedcentral.com/1471-2326/6/6
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allelic forms of the mouse Plg gene have been reported for
B6 and A/J mice [40]. Plg concentration was increased in
A/J mice compared to B6 mice. Although we did not
detect differences in Plg structure, this would not exclude
possible functional differences. A congenic strain (specific
for a homosomic region from A/J and the remaining Chr
and background is from B6 mice) of A/J chromosome 17
that includes the Plg gene was tested in the bleeding assay.
Values for bleeding and rebleeding in this congenic strain
were similar to values from B6 mice, indicating that the
QTL is not Plg. There are genes for other proteases and
matrix proteins that reside on chromosome 17 in addition
to unknown genes. DNA base pair sequence data for the
PAI-1 gene or the α2-antiplasmin gene in B6 and A/J mice
have reported no differences [51], but regulatory genes
upstream of the coding region may be important. Our
results suggest that novel or unknown genes may interact
with the Plg system components to modify their function.
In summary, this study reports marked differences in two
inbred strains of mice, B6 and A/J, in arterial thrombosis
formation in a FeCl3 vascular injury model, rebleeding
time in a tail bleeding assay, plasminogen function, and
tissue and vessel collagen deposition. Three chromo-
somes from A/J mice were identified that had QTL for
rebleeding time. The genes may interact with components
in the Plg network and modulate arterial occlusion time.
Conclusion
The marked independent differences demonstrated in the
B6 and A/J mice can be exploited to identify genetic deter-
minants of thrombosis and haemostasis. Our results of
the CSS screening suggest that novel or unknown genes
can be used to identify the genes responsible for the traits
related to arterial thrombosis, tail bleeding/rebleeding
and vessel extracellular matrix. Identification of differ-
ences in the parent strains, such as those described in this
study, and screening of the CSS is a first-step in the discov-
ery of new genetic determinants of thrombotic risk.
Abbreviations
B6 = C57BL/6J
CSS = chromosome substitution strains
CSS-# = B6-Chr #A/J
CSS-#F1 = (B6 × CSS-#)F1
WT = wild-type
-/- = deficient
Plg = plasminogen
PAI-1 = plasminogen activator inhibitor-1
tPA = tissue plasminogen activator
uPA = urokinase plasminogen activator
SEM = standard error of the mean
QTL = quantitative trait locus
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
JHP conceived and designed the study, coordinated the
experiments and drafted the manuscript. AS developed
and performed the tail bleeding assay and participated in
drafting the manuscript. EH carried out the vascular injury
model and analyses and the tail bleeding assay, partici-
pated in the tail collagen analyses, and coordination of
the mouse breeding. JS participated in the analysis of the
vascular injury model results and collagen analyses. JHN
and AHE provided the CSS breeding pairs, JHN partici-
pated in discussions of the results, and JBS and JHN devel-
oped the CSS. All the authors have read and approved the
final manuscript.
Acknowledgements
The authors thank Dr. A. Vasanji, Shiyang Wang, and Jenna Saraniti for 
assistance with image analyses, David Hellard for performing the blood 
pressure measurements, Dr. Y.Shchurina for the plasminogen analyses, 
Drs. Lindsey Burrage and Jonathan Smith for helpful discussions, and Robin 
Lewis for assistance with manuscript preparation. This study was supported 
by grants from NIH, HL17964, HL65204, HL078701 (JHP), T32 HL07914 
(AS), and RR12305 (JHN).
References
1. Marenberg ME, Risch N, Berman LF, Floderus B, de Faire U: Genetic
susceptibility to death from coronary heart disease in a study
of twins.  N Engl J Med 1994, 330:1041-1046.
2. Rosenberg RD, Aird WC: Vascular-bed-specific hemostasis and
hypercoagulable states.  N Engl J Med 1999, 340:1555-1564.
3. Caprini JA, Glase CJ, Anderson CB, Hathaway K: Laboratory mark-
ers in the diagnosis of venous thromboembolism.  Circulation
2004, 109:I4-I8.
4. Humphries SE, Lane A, Dawson S, Green FR: The study of gene-
environment interactions that influence thrombosis and
fibrinolysis. Genetic variation at the loci for factor VII and
plasminogen activator inhibitor-1.  Arch Pathol Lab Med 1992,
116:1322-1329.
5. Nesheim M: Thrombin and fibrinolysis.  Chest 2003, 124:33S-39S.
6. Voetsch B, Loscalzo J: Genetic determinants of arterial throm-
bosis.  Arterioscler Thromb Vasc Biol 2004, 24:216-229.
7. Lusis AJ: Atherosclerosis.  Nature 2000, 407:233-241.
8. Surwit RS, Feinglos MN, Rodin J, Sutherland A, Petro AE, Opara EC,
Kuhn CM, Rebuffe-Scrive M: Differential effects of fat and
sucrose on the development of obesity and diabetes in
C57BL/6J and A/J mice.  Metabolism 1995, 44:645-651.
9. Paigen B, Morrow A, Holmes P, Brandon C, Mitchell D: Variation in
susceptibility to atherosclerosis among inbred strains of
mice.  Atherosclerosis 1985, 57:65-73.BMC Blood Disorders 2006, 6:6 http://www.biomedcentral.com/1471-2326/6/6
Page 11 of 12
(page number not for citation purposes)
10. Harmon KJ, Couper LL, Lindner V: Strain-dependent vascular
remodeling phenotypes in inbred mice.  Am J Pathol 2000,
156:1741-1748.
11. Nadeau JH, Singer JB, Matin A, Lander ES: Analysing complex
genetic traits with chromosome substitution strains.  Nat
Genet 2000, 24:221-225.
12. Petryshen TL, Kirby A, Hammer RPJ, Purcell S, O'leary SB, Singer JB,
Hill AE, Nadeau JH, Daly MJ, Sklar P: Two quantitative trait Loci
for prepulse inhibition of startle identified on mouse chro-
mosome 16 using chromosome substitution strains.  Genetics
2005, 171:1895-1904.
13. Singer JB, Hill AE, Burrage LC, Olszens K, Song J, Justice M, O'Brien
WE, Conti DV, Witte JS, Lander ES, Nadeau JH: Genetic dissection
of complex traits with chromosome substitution strains of
mice.  Science 2004, 304:445-448.
14. Ernest S, Hosack A, WE O, Rosenblatt DS, JH N: Homocysteine
levels in A/J and C57BL/6J mice: genetic, diet, gender and
parental effects.  Physiol Genomics 2005, 21:404-410.
15. Carmeliet P, Kieckens L, Schoonjans L, Ream B, Van Nuffelen A, Pren-
dergast G, Cole M, Bronson R, Collen D, Mulligan RC: Plasminogen
activator inhibitor-1 gene-deficient mice. I. Generation by
homologous recombination and characterization.  J Clin Invest
1993, 92:2746-2755.
16. Ploplis VA, Carmeliet P, Vazirzadeh S, Van Vlaenderen I, Moons L,
Plow EF, Collen D: Effects of disruption of the plasminogen
gene in mice on thrombosis, growth and health.  Circulation
1995, 92:2585-2593.
17. Sha J, McCullough B, Hart E, Nassir F, NO D, Hoover-Plow J: Apo(a)
promotes throombosis in a vascular injury model by a mech-
anism independent of plasminogen.  J Thromb Haemost 2005,
3:2281-2289.
18. Zhu Y, Farrehi PM, Fay WP: Plasminogen activator inhibitor
type 1 enhances neointima formation after oxidative vascu-
lar injury in atherosclerosis-prone mice.  Circulation 2001,
103:3105-3110.
19. Farrehi PM, Ozaki CK, Carmeliet P, Fay WP: Regulation of arterial
thrombolysis by plasminogen activator inhibitor-1 in mice.
Circulation 1998, 97:1002-1008.
20. Chandler W, Loo SC, Nguyen SV, Schmer G, Stratton JR: Standard-
ization of methods for measuring plasminogen activator
inhibitor activity in human plasma.  Clin Chem 1989, 35:787-793.
21. Levin EG, Miles LA, Fless GM, Scanu AM, Baynham P, Curtiss LK, Plow
EF: Lipoproteins inhibit the secretion of tissue plasminogen
activator from human endothelial cells.  Arterioscler Thromb
1994, 14:438-442.
22. Mussoni L, Raczka E, Chmielewska J, Donati MB, Latallo ZS: Plas-
minogen assay in rabbit, rat and mouse plasma using the
chromogenic substrate s-2251.  Thromb Res 1979, 15:341-349.
23. Lijnen HR, Wagner EF, Collen D: Plasminogen-dependent and -
independent proteolytic activity of murine endothelioma
cells with targeted inactivtion of fibrinolytic genes.  Thromb
Haemost 1997, 77:362-367.
24. Day SM, Reeve JL, Myers DD, Fay WP: Murine thrombosis mod-
els.  Thromb Haemost 2004, 92:486-494.
25. Ibrahim J, Miyashiro JK, Berk BC: Shear stress is differentially
regulated among inbred rat strains.  Circ Res 2003,
92:1001-1009.
26. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ: Leptin-
dependent platelet aggregation and arterial thrombosis sug-
gests a mechanism for atherothrombotic disease in obesity.
J Clin Invest 2001, 108:1533-1540.
27. Matsuno H, Kozawa O, Okada K, Ueshima S, Matsuo O, Uematsu T:
Inhibitors of fibrinolytic components play different roles in
the formation and removal of arterial thrombus in mice.  J
Cardiovasc Pharmacol 2002, 39:278-286.
28. Sweeney JD, Novak EK, Reddington M, Takeuchi KH, Swank RT: The
RIIIS/J inbred mouse strain as a model for von Willebrand
disease.  Blood 1990, 76:2258-2265.
29. Broze GJ, ZF Y, N L: A tail vein bleeding time model and
delayed bleeding in hemophiliac mice.  Thromb Haemost 2001,
85:747-748.
30. Kato K, Martinez C, Russell S, Nurden P, Nurden A, Fiering S, Ware
J: Genetic deletion of mouse platelet glycoprotein Ibb pro-
duced a bernard-soulier phenotype with increased a-granule
size.  Blood 2004, 104:2339-2344.
31. Hamilton JR, Cornelissen I, Coughlin SR: Impaired hemostasis and
protection against thrombosis in protease-activated recep-
tor 4-deficient mice is due to lack of thrombin signaling in
platelets.  J Thromb Haemost 2004, 2:1429-1435.
32. Matsuno H, Kozawa O, Niwa M, Ueshima S, Matsuo O, Collen D,
Uematsu T: Differential role of components of the fibrinolytic
system in the formation and removal of thrombus induced
by endothelial injury.  Thromb Haemost 1999, 81:601-604.
33. Ryan MJ, Didion SP, Davis DR, Faraci FM, Sigmund CD: Endothelial
dysfunction and blood pressure variability in selected inbred
mouse strains.  Arterioscler Thromb Vasc Biol 2002, 22:42-48.
34. Hoit BD, Kiatchoosakun S, Restivo J, Kirkpatrick D, Olszens K, Shao
H, Pao YH, Nadeau JH: Naturally occurring variation in cardio-
vascular traits among inbred mouse strains.  Genomics 2002,
79:679-685.
35. Mattson DL: Comparison of arterial blood pressure in differ-
ent strains of mice.  Am J Hypertens 2001, 14:405-408.
36. Woo DD, Kurtz I: Mapping blood pressure loci in (A/J x B6)F2
mice.  Physiol Genomics 2003, 15:236-242.
37. Nassar T, Haj-Yehia A, Akkawi S, Kuo A, Bdeir K, Mazar A, Cines DB,
Higazi AAR: Binding of urokinase to low density lipoprotein-
related receptor (LRP) regulates vascular smooth muscle
cell contraction.  J Biol Chem 2002, 277:40499-40504.
38. Mark AL, Shaffer RA, Correia MLG, Morgan DA, Sigmund CD, Hay-
nes WG: Contrasting blood pressure effects of obesity in lep-
tin-deficient ob/ob mice and agouti yellow obese mice.  J
Hypertens 1999, 17:1949-1953.
39. Swoap SJ: Altered leptin signaling is sufficient, but not
required, for hypotension associated with caloric restriction.
Am J Physiol Heart Circ Physiol 2001, 281:H2473-H2479.
40. Degen SJF, Bell SM, Schaefer LA, Elliott RW: Characterization of
the cDNA coding for mouse plasminogen and localization of
the gene to mouse chromosome 17.  Genomics 1990, 8:49-61.
41. Coleman DL, Hummel KP: The influence of genetic background
on the expression of the obese (Ob) gene in the mouse.  Dia-
betologia 1973, 9:287-293.
42. Hasty AH, Shimano H, Osuga J, Namatame I, Takahashi A, Yahagi N,
Perrey S, Iizuka Y, Tamura Y, Amemiya-Kudo M, Yoshikawa T, Oka-
zaki H, Ohashi K, Harada K, Matsuzaka T, Sone H, Gotoda T, Nagai
R, Ishibashi S, Yamada N: Severe hypercholesterolemia, hyper-
triglyceridemia, and atherosclerosis in mice lacking both lep-
tin and the low density lipoprotein receptor.  J Biol Chem 2001,
276:37402-37408.
43. Schafer K, Halle M, Goeschen C, C D, Pynn M, Loskutoff DJ, Konstan-
tinides S: Leptin promotes vascular remodeling and neointi-
mal growth in mice.  Arterioscler Thromb Vasc Biol 2004,
24:112-117.
44. Hoover-Plow J, Ellis J, Yuen L: In vivo plasminogen deficiency
reduces fat accumulation.  Thromb Haemost 2002, 87:1011-1019.
45. Xiao Q, Danton MJS, Witte DP, Kowala MC, Valentine MT, Bugge
TH, Degen JL: Plasminogen deficiency accelerates vessel wall
disease in mice predisposed to atherosclerosis.  Proc Natl Acad
Sci U S A 1997, 94:10335-10340.
46. Shi C, Russell ME, Bianchi C, Newell JB, Haber E: Murine model of
accelerated transplant arteriosclerosis.  Circ Res 1994,
75:199-207.
47. Carmeliet P, Moons L, Ploplis V, Plow E, Collen D: Impaired arte-
rial neointima formation in mice with disruption of the plas-
minogen gene.  J Clin Invest 1997, 99:200-208.
48. Drew AF, Tucker HL, Kombrinck KW, Simon DI, Bugge TH, Degen
JL: Plasminogen is a critical determinant of vascular remod-
eling in mice.  Circ Res 2000, 87:133-139.
49. Carmeliet P, Collen D: Molecular genetics of the fibrinolytic
and coagulation systems in haemostasis, thrombogenesis,
restenosis and atherosclerosis.  Curr Opin Struct Biol 1997,
8:118-125.
50. Ploplis VA, Cornelissen I, Sandoval-Cooper MJ, Weeks L, Noria FA,
Castellino FJ: Remodeling of the vessel wall after copper-
induced injury is highly attenuated in mice with a total defi-
ciency of plasminogen activator inhibitor-1.  Am J Pathol 2001,
158:107-117.
Pre-publication history
The pre-publication history for this paper can be accessed
here:Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Blood Disorders 2006, 6:6 http://www.biomedcentral.com/1471-2326/6/6
Page 12 of 12
(page number not for citation purposes)
http://www.biomedcentral.com/1471-2326/6/6/prepub